Zovegalisib

Phase 3

Relay Therapeutics

Zovegalisib is one of 3 therapeutic programs targeting PIK3CA Mutation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PIK3CA MutationRecruiting

PIK3CA MutationPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in PIK3CA Mutation

#DrugCompanyPhaseTrials

Faslodex

FFresenius Kabi USA, LLC

Phase 3

1 2

Copanlisib Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 3

Zovegalisib

Relay Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

PIK3CA Mutation

NCT06982521

Clinical

Trials by Indication[1]

PIK3CA Mutation1 trial

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

Recruiting· Relay Therapeutics logo

Relay Therapeutics·Phase 3·NCT06982521·540 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zovegalisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Zovegalisib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Relay Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Relay Therapeutics

Zovegalisib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

PIK3CA Mutation1 trial

References

Drug Info

Quick Facts

Related News